United States-based Halodine LLC has collaborated with Emery Pharma, a boutique contract research and development company, it was reported on Thursday.
The collaboration is aimed at advancing the development of Halodine's proprietary antiseptic platform for COVID-19.
The partnership will see Emery Pharma's use its experience in antimicrobial and antiviral screening and drug development, while Halodine is to use its expertise in topical antiviral drug development.
Emery Pharma says that it will leverage its microbiology, virology, and bioanalytical experience to aid in developing this novel product, as well as other drugs to help treat COVID-19.
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease